Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05385601
Other study ID # e-VOG-Young Athletes-Extension
Secondary ID
Status Completed
Phase
First received
Last updated
Start date May 17, 2022
Est. completion date June 8, 2022

Study information

Verified date July 2022
Source Association de Recherche Bibliographique pour les Neurosciences
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study aims to compare measurements obtained through the e-VOG application (mobile application, usable on smartphones or tablets, to record eye movements) with measurements from the standard video-oculography device (Eye-Tracker®T2), in young athletes. This study also aims to correlate these measurements with volumetric data from cerebral imaging (if MRI done in routine care at the same period, more or less 1 month).


Description:

e-VOG Young athletes is a collaborative study between the Memory Center of the Rainier III Center (Princess Grace Hospital, Monaco), the Neurology Department of Nice University Hospital (France), and the AS Monaco Football Academy medical team. Memory Center of the Rainier III Center is expert in eye-tracking and is equipped with a standard video-oculography device (Eye-Tracker®T2), which records eye movements at a high frequency and measures saccades parameters (latency, speed, amplitudes etc...). e-VOG is a mobile application, home-developed by the Neurology Department team of Nice University Hospital, to measure eye movements. In the continuity of the e-VOG(YA) study (NCT05211752), we set-up study named e-VOG-Young Athletes-Extension. This study will increase the number of assessments carried out (standard video-oculography assessment versus e-VOG digital assessment) in a population of athletes without major health problems, and who have not presented concussion, in order to meet more powerfully the main objective of the e-VOG(YA) study. It will also make it possible to observe whether there is a correlation between disturbed oculomotor movements, oculomotor anomalies and volumetric data measured by cerebral MRI (obtained using automatic segmentation software on cerebral regions specifically involved in the eye movement control).


Recruitment information / eligibility

Status Completed
Enrollment 36
Est. completion date June 8, 2022
Est. primary completion date June 8, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 15 Years to 19 Years
Eligibility Inclusion Criteria: - Young Athletes from AS Monaco Academy - referred by AS Monaco Medical Team to perform a video-oculography (Eye-Tracking) examination as part of routine care. - covered by a health insurance system - volunteer, able to give free, informed and written consent. Exclusion Criteria: - General anaesthesia within 3 months. - Head trauma within 3 months - Neurological, ophthalmological or general pathology preventing the realization of a video-oculography examination. - Oculomotor abnormality detectable on clinical examination by the neurologist prescribing the standard video-oculography examination.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
eVOG (Mobile VideoOculoGraphy)
Eyes movements assessed with e-VOG (mobile application developed on an iPad, that uses the face detection features of the front camera to detect and record eye movements). Study duration is about 20 minutes, the day the subject performs his standard video-oculography examination in routine care (using Eye-Tracker®T2)

Locations

Country Name City State
Monaco Centre Mémoire / Centre de Gérontologie Clinique Rainier III / Princess Grace Hospital Monaco

Sponsors (4)

Lead Sponsor Collaborator
Association de Recherche Bibliographique pour les Neurosciences Association Sportive Monaco Football Club, Centre Hospitalier Princesse Grace, Centre Hospitalier Universitaire de Nice

Country where clinical trial is conducted

Monaco, 

Outcome

Type Measure Description Time frame Safety issue
Primary Oculomotor profiles concordance Analyze of the concordance of the profiles obtained between the e-VOG digital assessment and the standard video-oculography assessment.
Evaluation criteria: For each assessment, patients will be classified according to the number of oculomotor abnormality observed (based on identified parameters assessments: latency / speed / gain / altered ocular pursuits / fixation disorders / presence of internuclear ophthalmoplegia), in accordance with the literature standards
Day 0
Secondary Latency during horizontal reflex saccades Measure of Latency during an horizontal reflex saccades paradigm with e-VOG Compared to the one performed with standard video-oculography device.
Evaluation criteria: latency (reaction time in ms).
Day 0
Secondary Latency during vertical reflex saccades Measure of Latency during a vertical reflex saccades paradigm with e-VOG Compared to the one performed with standard video-oculography device.
Evaluation criteria: latency (reaction time in ms).
Day 0
Secondary Latency during horizontal voluntary saccades Measure of Latency during an horizontal volontary saccades paradigm with e-VOG Compared to the one performed with standard video-oculography device.
Evaluation criteria: latency (reaction time in ms).
Day 0
Secondary Velocity during horizontal reflex saccades Measure of Velocity during an horizontal reflex saccades paradigm with e-VOG Compared to the one performed with standard video-oculography device.
Evaluation criteria: velocity (mean and peak velocity) in °/s.
Day 0
Secondary Velocity during vertical reflex saccades Measure of Velocity during a vertical reflex saccades paradigm with e-VOG Compared to the one performed with standard video-oculography device.
Evaluation criteria: velocity (mean and peak velocity) in °/s.
Day 0
Secondary Inhibition capacity Measure of inhibition capacity performance during an antisaccades" paradigm with e-VOG Compared to the one evaluated with standard video-oculography device.
Evaluation criteria: percentage of errors.
Day 0
Secondary Internuclear ophthalmoplegia (INO) detection Highlight presence/absence of INO with e-VOG Compared to standard video-oculography device.
Evaluation criteria: INO is present if calculated ratio of abducting to adducting eye movement (both mean and peak velocity) is >1.
Day 0
Secondary Fixations impairments detection Highlight presence/absence of Fixations impairments with e-VOG Compared to standard video-oculography device.
Evaluation criteria: presence/absence/frequency of square wave-jerks, nystagmus, flutters.
Day 0
Secondary Impairment of horizontal smooth pursuit Highlight Impairment of horizontal smooth pursuit with e-VOG Compared to standard video-oculography device.
Evaluation criteria: presence/absence of saccade and perturbation.
Day 0
Secondary Impairment of vertical smooth pursuit Highlight Impairment of horizontal smooth pursuit with e-VOG Compared to standard video-oculography device.
Evaluation criteria: presence/absence of saccade and perturbation.
Day 0
Secondary Imaging data correlation: Total brain volume Analyze if there are correlation between oculomotor abnormalities and volumetric data measured by brain MRI.
Evaluation criteria: Total brain volume (Data from cerebellar MRI performed in routine care, obtained using automatic segmentation software).
Day 0
Secondary Imaging data correlation: Frontal Lobe Volume Analyze if there are correlation between oculomotor abnormalities and volumetric data measured by brain MRI.
Evaluation criteria: Frontal Lobe Volume (Data from cerebellar MRI performed in routine care, obtained using automatic segmentation software).
Day 0
Secondary Imaging data correlation: Parietal Lobe Volume Analyze if there are correlation between oculomotor abnormalities and volumetric data measured by brain MRI.
Evaluation criteria: Parietal Lobe Volume (Data from cerebellar MRI performed in routine care, obtained using automatic segmentation software).
Day 0
Secondary Imaging data correlation: Volume of additional motor areas Analyze if there are correlation between oculomotor abnormalities and volumetric data measured by brain MRI.
Evaluation criteria: Volume of additional motor areas (Data from cerebellar MRI performed in routine care, obtained using automatic segmentation software).
Day 0
Secondary Imaging data correlation: Basal ganglia volume Analyze if there are correlation between oculomotor abnormalities and volumetric data measured by brain MRI.
Evaluation criteria: Basal ganglia volume (Data from cerebellar MRI performed in routine care, obtained using automatic segmentation software).
Day 0
Secondary Imaging data correlation: Total thalamic volume Analyze if there are correlation between oculomotor abnormalities and volumetric data measured by brain MRI.
Evaluation criteria: Total thalamic volume (Data from cerebellar MRI performed in routine care, obtained using automatic segmentation software).
Day 0
Secondary Imaging data correlation: cerebellar volume Analyze if there are correlation between oculomotor abnormalities and volumetric data measured by brain MRI.
Evaluation criteria: Cerebellar volume (Data from cerebellar MRI performed in routine care, obtained using automatic segmentation software).
Day 0
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1